Targeted Project 2
Targeted Project (TP2) involves a retrospective study of the natural history and genetic subtypes of ALS patients using data extracted from TRICALS Partners in Ireland, Netherlands, Belgium, UK (2 sites), Spain, Sweden, France and Italy.
This study will investigate the natural history of ALS in European population-based datasets in terms of rate of functional decline, time to key clinical milestones, and survival. Findings from this study will provide valuable information that will support new drug development for ALS in the United States and Europe. The data acquisition and integration will provide for the first iterations of the ICT Patient Data Platform.
Data about the natural history of genetic subtypes of ALS will be critical in demonstrating the value of future drug therapies to governments and payors. Access to such data will be greatly facilitated by Precision ALS.